GLAND PHARMA share price has plunged 4% and is presently trading at Rs 1,779.8.
Meanwhile, the BSE HEALTHCARE index is at 44,348.6 (up 0.5%).
Among the top losers in the BSE HEALTHCARE index today are NARAYANA HRUDAYALAYA (down 2.3%) and HIKAL CHEMIC (down 1.8%).
Natco Pharma (up 2.7%) and Sun Pharma (up 2.4%) are among the top gainers today.
Over the last one year, GLAND PHARMA has moved up from Rs 1,659.7 to Rs 1,779.8, registering a gain of Rs 120.1 (up 7.2%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,800.9 to 44,348.6, registering a gain of 59.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 181.5%), SUVEN PHARMACEUTICALS (up 121.7%) and Glenmark Pharma (up 115.3%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 85,620.6 (down 0.3%).
The top losers among the BSE Sensex today are Power Grid Corp. (down 2.8%) and Bharti Airtel (down 2.4%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 26,185.8 (down 0.1%). Power Grid Corp. and Bharti Airtel are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,023.7 to 85,620.6, registering a gain of 19,596.9 points (up 29.7%).
GLAND PHARMA net profit fell 25.9% YoY to Rs 1,438 million for the quarter ended June 2024, compared to a profit of Rs 1,941 million a year ago. Net sales rose 16.0% to Rs 14,017 million during the period as against Rs 12,087 million in April-June 2023.
For the year ended March 2024, GLAND PHARMA reported 1.1% decrease in net profit to Rs 7,725 million compared to net profit of Rs 7,810 million during FY23. Revenue of the company grew 56.3% to Rs 56,647 million during FY24.
The current Price to earnings ratio of GLAND PHARMA, based on rolling 12 month earnings, stands at 40.6.
Equitymaster requests your view! Post a comment on "GLAND PHARMA Plunges 4%; BSE HEALTHCARE Index Up 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!